Yeah, so, you know, this was a registrational trial, and there will be conversations with authorities specifically in that setting post-CDK 4/6. In the trial, patients were also allowed if they’d had one additional line of therapy, so it was kind of a second and third line trial in some ways, but 80% of patients had only received one prior in the metastatic setting...
Yeah, so, you know, this was a registrational trial, and there will be conversations with authorities specifically in that setting post-CDK 4/6. In the trial, patients were also allowed if they’d had one additional line of therapy, so it was kind of a second and third line trial in some ways, but 80% of patients had only received one prior in the metastatic setting. So I think this is where it’s immediately most actionable. Certainly, you know, Vepdegustrant is a novel endocrine backbone. And as we discovered with other endocrine agents, we certainly can combine, whether that’s with CDK4/6 inhibitors, whether that’s with PI3K inhibitors or novel CDK2, CDK6, et cetera. And we also could imagine this potentially going earlier line, first line with CDK4/6s or even in the higher risk adjuvant setting where some other oral SERDs are being explored. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
